Human Placenta-Derived Cells PDA001- (cenplacel-L) + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stroke, Acute
Conditions
Stroke, Acute, Middle Cerebral Artery Stroke, Posterior Cerebral Artery Stroke
Trial Timeline
Mar 1, 2011 → Mar 1, 2013
NCT ID
NCT01310114About Human Placenta-Derived Cells PDA001- (cenplacel-L) + Placebo
Human Placenta-Derived Cells PDA001- (cenplacel-L) + Placebo is a phase 2 stage product being developed by Celularity for Stroke, Acute. The current trial status is terminated. This product is registered under clinical trial identifier NCT01310114. Target conditions include Stroke, Acute, Middle Cerebral Artery Stroke, Posterior Cerebral Artery Stroke.
What happened to similar drugs?
7 of 20 similar drugs in Stroke, Acute were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01310114 | Phase 2 | Terminated |
Competing Products
20 competing products in Stroke, Acute